Internal Medicine, Gastroenterology · Scottsdale, AZ
NPI
1982714960
Since 2006
Specialty
Internal Medicine, Gastroenterology
Code 207RG0100X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
9767 N 91st St, #100
Scottsdale, AZ, 85258
Phone (480) 860-1990
Groups this clinician bills Medicare through
Medicare paid, 2024
$158K
1,729 services
Medicare patients, 2024
681
Average age 74
Drug cost, 2024
$167K
852 prescriptions
Company payments, 2025
$185K
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Daniel A Meline was code 99214 (office e&m - established), 255 times for 242 patients. In total Daniel A Meline billed 1,729 services in 24 codes, and Medicare paid $158K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2017-02-17.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 255 | 242 | $89.39 | $23K |
| 45380 Lower GI Endoscopy - Other | Facility | 248 | 248 | $146.17 | $36K |
| 99204 Office E&M - New | Office | 216 | 216 | $102.61 | $22K |
| 43239 Upper GI Endoscopy | Facility | 168 | 162 | $83.87 | $14K |
| 99203 Office E&M - New | Office | 137 | 137 | $77.59 | $11K |
| G0105 Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 112 | 112 | $173.26 | $19K |
| 45385 Colonoscopy - Lesion Removal | Facility | 47 | 46 | $202.56 | $9,520 |
| G0121 Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 46 | 46 | $173.45 | $7,979 |
| 99213 Office E&M - Established | Office | 40 | 39 | $66.26 | $2,651 |
| 99215 Office E&M - Established | Office | 13 | 13 | $131.69 | $1,712 |
| 45378 Lower GI Endoscopy - Other | Facility | 12 | 12 | $127.78 | $1,533 |
By year: 2022 $130K for 1,303 services; 2023 $140K for 1,412 services; 2024 $158K for 1,729 services.
Medicare prescription drug claims, 2024
In 2024, the drug Daniel A Meline prescribed most often to Medicare patients was Pantoprazole Sodium, with 325 prescriptions and refills. In total Daniel A Meline wrote 852 Medicare prescriptions that cost $167K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Pantoprazole Sodium Generic | 325 | 889 | 105 | $4,537 |
| Sutab Sod Sulf/Pot Chloride/Mag Sulf | 206 | 206 | 204 | $33K |
| Omeprazole Generic | 54 | 146 | 16 | $329 |
| Voquezna Vonoprazan Fumarate | 41 | 55 | 19 | $35K |
| Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates | 25 | 25 | 25 | $1,518 |
| Linzess Linaclotide | 25 | 60 | 11 | $32K |
| Lansoprazole Generic | 17 | 51 | Under 11 | $316 |
| Dexlansoprazole Dr Dexlansoprazole | 17 | 43 | Under 11 | $6,977 |
| Famotidine Generic | 14 | 42 | Under 11 | $133 |
| Budesonide Dr Budesonide | 14 | 17 | Under 11 | $532 |
| Esomeprazole Magnesium Generic | 13 | 40 | Under 11 | $565 |
| Mesalamine Generic | 12 | 22 | Under 11 | $11K |
| Azathioprine Generic | 12 | 23 | Under 11 | $271 |
Brand drugs: 313 claims; generic drugs: 539 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Daniel A Meline $185K ($185K in general payments such as food, travel and fees) from 11 companies. The largest payer was Aimmune Therapeutics, Inc. with $107K.
| Company | Payments | Amount |
|---|---|---|
| Aimmune Therapeutics, Inc. | 129 | $107K |
| Phathom Pharmaceuticals, Inc. PHAT | 105 | $67K |
| Abbvie Inc. ABBV | 12 | $10K |
| Genzyme Corporation SNY | 11 | $305 |
| Janssen Biotech, Inc. JNJ | 2 | $56.26 |
| Orphalan Inc | 1 | $28.5 |
| Ipsen Biopharmaceuticals, Inc IPN.PA | 1 | $27.54 |
| Lilly USA, LLC LLY | 1 | $21.86 |
| Madrigal Pharmaceuticals MDGL | 1 | $18.72 |
| Celltrion USA Inc. 068270.KS | 1 | $15.1 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.